Marwah Medicine

FMGE, INICET, Medicine, NEET PG, NEETPG2024, NExT, NExT Exam

Contraindications to thrombolysis in Myocardial infarction

Fibrinolytic agents should be given with 30 minutes of arrival to non-PCI capable hospital where transport to PCI capable hospital is not possible or has delay beyond 120 minutes Current recommended regimen is tPA 15 mg bolus followed by 50 mg Intravenously over 30 minutes and 35 mg over the next 30 minutes. In contrast tenecteplase can be given as weight based intravenous bolus over 10 seconds. Clear Contraindications are remembered by mnemonic: HAS-BLEED 1.       Hypertension marked elevation of BP > 180/110 mm Hg at any time during presentation 2.       Aortic dissection suspected 3.       Stroke: Hemorrhagic at any time 4.       Stroke: Non-hemorrhagic in last 1 year 5.       Bleeding (active internal bleed excluding menses) Relative contraindications to fibrinolytic therapy Mnemonic: RIP – AB AB implies has allergy or Bleed in eye/GIT or bleed risk due to hypertension Recent invasive surgical procedure in last 2 weeks INR> 2 due to current use of OAC Prolonged CPR (> 10 minutes) Pregnancy Risk of Allergic reaction with received STK within preceding 5 days to 2 years Hemorrhagic diabetic retinopathy Active Peptic ulcer disease Severe Hypertension   Hemorrhage is the most serious and most frequent complication of thrombolysis. Hemorrhagic stroke can occur in 0.5 to 0.9% of patients treated with fibrinolytic agents

FMGE, INICET, Medical, Medicine, NEET PG, NExT Exam

Must Read Topics in General Medicine for INICET Examination

The INICET tends to blend image-based questions with clinical vignettes, emphasizing practical application over rote learning. Clinical reasoning, such as interpreting lab values or recognizing syndromes from case scenarios, is prioritized. Also, several questions in the last few papers have integrated basic sciences like pathology and microbiology into clinical contexts, so revisiting integrated concepts may give you an edge. For the November INI-CET (Institute of National Importance Combined Entrance Test), General Medicine is a key subject. The exam tends to emphasize clinical knowledge, diagnostics, management protocols, and recent updates. Here’s a structured list of must-know topics for General Medicine preparation: Cardiology – ECG interpretation– MI, arrhythmias, heart blocks, electrolyte disturbances Horizontal ST depression with upright T waves + R/S > 1 in lead V2 HTN patient with SOB and palpitations. On examination, HR= 120 min, irregular with BP= 90/60 mm Hg. Bilateral crackles in both lung fields is seen. Which is not correct? a. Rate control with esmolol b. Warfarin is not used non -valvular atrial fibrillation c. Rhythm control with Amiodarone d. DC shock is not given in persistent AF a a,b b,c b,d – Brugada syndrome vs TTCM -Acute Coronary Syndrome (STEMI/NSTEMI management) – Congestive Heart Failure (CHF) and NYHA Classification – Infective Endocarditis (update ISCVD 2023 update modified Duke’s criteria) – Hypertension – Aortic dissection management based on type A and type B Neurology – Stroke – Types, NIHSS score, thrombolysis, secondary prevention Would you perform thrombolysis a patient with weakness of face and arm weakness for last 1 hour with normal CT scan – Epilepsy – types and GCSE management – Parkinson’s disease vs HD vs PSP – Multiple Sclerosis and Guillain-Barré Syndrome – Meningitis/Encephalitis – Empirical antibiotics, CSF findings – Headache – Migraine, cluster headache, tension headache vs SAH vs GCA Endocrinology – Diabetes Mellitus – Diagnostic criteria of DKA/HHS management – Thyroid Disorders – Hypo- and hyperthyroidism, nodules, malignancy markers – Adrenal Disorders – Addison’s disease, Cushing’s syndrome   – Pituitary Disorders – Acromegaly, SIADH, DI (diabetes insipidus) – MEN Syndrome Pulmonology – Sleep Apnea Syndrome and obesity hypoventilation syndrome – Pulmonary Embolism and DVT – Risk factors, anticoagulation therapy Biker had polytrauma and develops breathing difficulty after 12 hours of injury. Sp02= 85%CT chest is shown. Echo shows Normal cardiac parameters. a. Fat embolism b. Pulmonary embolism c. ARDS d. Pneumothorax – COPD and Asthma – Harrison based guidelines, stepwise management – Interstitial Lung Diseases (ILDs) and Sarcoidosis – Tuberculosis (including MDR-TB management) Gastroenterology and Hepatology – Chronic Liver Disease and Cirrhosis – Child-Pugh score, MELD – Hepatitis – B graphs of Acute and chronic hepatitis B – GI bleed – Upper vs. lower, endoscopic management – Boerrhave vs Stomach volvulus vs Mallory Weiss vs Acute variceal bleeding Nephrology – Acute interstitial nephritis: Eosinophiluria — CIN vs Athero-embolic kidney disease -Fluid and Electrolyte Disorders – Sodium, potassium, calcium disturbances – Acute Kidney Injury (AKI) vs Chronic Kidney Disease (CKD) identification – Glomerulonephritis – RPGN, nephrotic vs nephritic syndrome – Renal replacement therapy – Hemodialysis, CRRT, peritoneal dialysis Rheumatology – Overlap syndrome – Anti synthetase syndrome vs Dermatomyositis vs Polymyositis Systemic Lupus Erythematosus (SLE) – Diagnostic criteria and antibodies – Rheumatoid Arthritis – Treatment protocols (DMARDs, biologics) – Vasculitis syndromes – ANCA-associated vasculitis, Takayasu’s arteritis – Gout and Pseudogout Infectious Diseases – Scrub typhus – Tropical Infections – Dengue, Malaria – HIV/AIDS – ART guidelines, opportunistic infections – COVID-19 and Post-COVID Syndromes -Sepsis and Septic Shock – Management protocols Hematology and Oncology – Leukemia and Lymphoma – Acute vs chronic, Hodgkin’s vs non-Hodgkin’s – Multiple Myeloma and Plasma Cell Disorders – Coagulation Disorders – DIC, hemophilia, thrombophilia – Paraneoplastic Syndromes General Topics & Miscellaneous – Acid-Base Disorders (ABG interpretation) – Shock – Types and management Study Tips  – Solve MCQs from previous INI-CET papers and clinical vignettes. – Focus on latest guidelines and protocols– These are frequently tested. – Give time to integrated questions involving multi-system involvement (e.g., heart and kidney-related disorders). This plan covers high-yield topics that are essential for the exam. Practice application-based questions regularly and ensure you revise the core topics thoroughly.

Medicine, NEET PG, NExT, NExT Exam

The Future of Anti-Hypertensive Therapy Explained

Once in 6 Months Blood Pressure Injection: The Future of Anti-Hypertensive Therapy Explained High blood pressure affects millions of people in India — and nearly 1 in 4 adults lives with hypertension, many without knowing it. The real challenge is not just treatment, but taking medicines regularly. Now imagine controlling blood pressure with just two injections per year. A new investigational therapy called zilebesiran may make this possible. Let’s understand it in simple language — clinically relevant, exam-focused, and easy to remember.   Featured Snippet: What Is the Once-in-6-Months Blood Pressure Injection? The once-in-6-months blood pressure injection refers to zilebesiran, an investigational RNA-interference therapy that lowers blood pressure by reducing liver production of angiotensinogen, a key component of the RAAS pathway. A single subcutaneous injection may provide blood pressure control for up to 6 months. 🇮🇳 Why This Matters: Hypertension in India Around 25–30% of Indian adults have hypertension. Many remain undiagnosed or irregular with treatment. Poor medication adherence leads to stroke, heart failure, and kidney disease. This makes long-acting therapies extremely interesting for the future of cardiovascular care. Related reading: [Hypertension management guide] (internal link)   Really? A Once-in-6-Months Anti-Hypertensive Drug? Yes — and this is what makes zilebesiran unique. Unlike conventional drugs that block hormones after formation, this drug works at the gene expression level. Daily pills block RAAS… RNAi stops RAAS from being born.   Mechanism of Action of Zilebesiran Target Liver-produced angiotensinogen (AGT) Method RNA interference (gene silencing) Effect ↓ Angiotensinogen ↓ Angiotensin II formation ↓ Vasoconstriction ↓ Blood pressure This means the drug acts upstream in the RAAS pathway, creating prolonged suppression. Related reading: [RAAS system explained simply] (internal link) Why Only Twice a Year? RNA-interference molecules remain active inside cells for a long time. Because of prolonged intracellular action: One subcutaneous injection suppresses AGT production for ~6 months. Dosing becomes biannual instead of daily. This mirrors what happened in diabetes care when therapy shifted from daily insulin to weekly injections. Clinical Trial Evidence — KARDIA Trials Phase II Study Highlights Double-blind, placebo-controlled trial 672 patients with hypertension Average baseline SBP: 143 mm Hg Key Findings Significant reduction in systolic BP vs placebo Additional benefit on top of standard medications BP lowering sustained for up to 6 months after one dose In some studies, the effect was similar to adding another oral antihypertensive drug. Why Is This a Big Deal? Solves adherence problems: Many patients forget daily pills. Twice-yearly injections could transform compliance. Continuous blood pressure control: No missed doses means more stable BP. Potential use in high-risk patients: Especially those uncontrolled despite multiple medications.   Limitations (Important Clinical Perspective) Still investigational (not routine therapy yet) Long duration means limited dose adjustment Side effects, if any, may persist longer Expected to be costlier initially So no — this does NOT replace current BP medicines yet.   Frequently Asked Questions (FAQ) ❓ What is the once-in-6-months BP injection? It is zilebesiran, an investigational RNA-interference drug that lowers blood pressure by reducing angiotensinogen production in the liver. Is zilebesiran available in India? No. It is currently under clinical trials and not yet approved for routine use. How does it differ from ACE inhibitors or ARBs? ACE inhibitors block hormone action, whereas zilebesiran prevents hormone production upstream. Who may benefit in the future? Patients with poor medication compliance or resistant hypertension may benefit if approved. Is it better than regular tablets? Not necessarily — current drugs remain effective and affordable.   Quick Summary Box Feature Zilebesiran Type RNA interference therapy Target Hepatic angiotensinogen Route Subcutaneous injection Frequency Every 6 months Status Investigational (Phase III underway) Major Advantage Improved adherence   Conclusion Will this replace daily BP tablets? Not yet. But it may represent the next evolution of hypertension treatment — where technology helps solve the biggest real-world problem: patients forgetting medicines. The future of cardiovascular pharmacology is moving toward long-acting, precision-based therapies — and zilebesiran may be one of the first steps in that direction.   References World Health Organization (WHO) ICMR Hypertension Data American College of Cardiology (ACC) trial presentations  

NExT Exam

How to study General medicine for the NExT Exam using an app

This blog is not about topics and subtopics to be studied but instead how to minimize distractions when you are trying to read a mega subject. If you want a list of must do topics then you can download it from https://marwahmedicine.com/newsite/wp-content/uploads/2020/07/HACKS-TO-READ-INTERNAL-MEDICINE.pdf So, you may have recently bought a Medicine app or complete course of an app but when you scroll through the same, the number of lessons is mind boggling and you are left wondering how to finish it. Once the novelty of having recently purchased the app has reduced, the distractions take over your mind – your partner is having a chat with you; your friend has posted a vacation story on Instagram; a dog is barking outside your window; it is freezing cold or sweltering hot; umpteen reasons why you don’t feel like studying. The reasons can be manifold, but in this blog you will find super tips on how to effectively use the app to increase your productivity and daily reading hours. Allocate a dedicated space: This space should be free from distractions and provide a comfortable atmosphere that encourages learning. Depending on your budget this space could be as simple as a desk and chair in a quiet corner of the house, or it could be a dedicated area that is equipped with a computer, comfortable seating, and other supplies. Use separate devices: Make it a point that your mobile phone with social media and the one used for Medicine app for NExT exam should be separate. Also ensure that when you sit down to study, you keep the mobile phone away from you, and on Do Not Disturb mode for a minimum of 30 minutes. Gradually increase this duration to minimum 150 minutes per session where you will not touch your mobile phone. The temptation to get up from your chair and check your phone will be high, so place it far from you, with screen facing down so that you are not able to see the app notification light turning on. This is the most critical step since you may have a craving to check your phone, but tell your mind to first finish the topic decided and then you will check your phone Cheap dopamine rush weakens the neurons: You can get a dopamine rush either by scrolling through Instagram or by working hard and getting questions and concepts right. Both will make you feel good but whichever option is easier will make your brain a slave and addicted to seeking more of the same behavior. You know how half an hour of study feels vis-à-vis half an hour of Instagram scrolling; study will make you feel sleepy and Instagram will give you a pseudo-rush. But it is better to tire out your neurons and then take a small nap rather than let those neurons get wasted with useless data. Set realistic goals. Before you start, set realistic goals for yourself. Think about what you want to achieve and how long it will take you to get there. This will help you stay motivated and on track. Don’t make a broad target for e.g. you will finish all of Rheumatology in one and half day, instead make a list of subtopics to be completed.  Take advantage of concise and short videos: I have deliberately kept the video sessions concise and this format limits something called cognitive load, providing just the right amount of information that can be absorbed properly. The beauty of online learning is that even if your lessons have not been created in this way, you can break them up into shorter segments, resulting in the same positive effect.  Rewind, pause, forward the video: Don’t be afraid to pause and rewind if feel you’ve NOT fully grasped a concept. Alternatively, if you think you have mastered a topic, feel free to speed up a video or simply fast forward.  Use You Tube sessions selectively: Use them only when your neurons are totally tired and exhausted.  Take Care of Yourself: Proper diet, adequate sleep, regular exercise, and breaks are key to elevating cerebral performance.   Keep hammering guys! #How_to_study_General_medicine #NExT_Exam

NExT, NExT Exam

Can ChatGPT clear NEET PG 2023 and FMG exam after clearing USMLE Exam?

Full form of ChatGPT is Chat Generative Pre-Trained Transformer. This open-source Artificial intelligence system started in Nov 2022 is a run way success and Elon musk is tweeting about it means it is something. This AI was able to get a decent score of 50 percent in one of most competitive exam in the world without any formal training. The guessing ability of the software is tremendous and learning for us as doctors is that cracking exams with controlled guess work is possible. Previous exam questions were fed into the AI took and surprisingly it had answers to clinical situations asked and this result was independently verified by two physicians. They had ensured that the question set asked to AI had not been fed into the data base of this system earlier. I personally think this software will get higher score in Indian NEET PG/ FMG exam where facts are asked and the system is loaded with facts over all these years. Can it replace doctors. Nopes ……. but it can surely make diagnostic algorithms easier to comprehend. It can guide doctors during emergency on next best step. It would be just like an airline pilot is aided by onboard computer to allow flight to go on auto mode similarly ChatGPT can help you manage the ward more effectively and can be trained to order labs and present lab reports and their interpretation to doctor for better case management. This tool has cracked even the US law school entrance test and Wharton business school exam apart from USMLE. You can also try this website and get a speedy detailed response on each topic in a crisp easy to understand form. In last couple of people have been enjoying this free source to write complex essays, poems and some websites have come up that say that you can write a book using this tool. Whether that would be true is yet to be seen but the medical profession can’t be replaced by robot making a diagnosis. ChatGPT can aid doctors though so that our accuracy increases #NEETPG2023 #NeXT exam #FMGexam #MCICOACHING #MEDICINETEACHER

INICET, Medical, Medicine, Medicine classes, NExT, NExT Exam

FDA Approves First Oral Drug for Dermatomyositis

Brepocitinib (Lisraya) Explained: Mechanism, VALOR Trial, Dose, Safety & Exam Pearls By Dr Deepak Marwah  |  Marwah Medicine A major change has arrived in dermatomyositis treatment. On August 27, 2026, the US FDA approved brepocitinib (Lisraya) tablets for adults with dermatomyositis, making it the first FDA-approved oral treatment specifically indicated for adult dermatomyositis. HIGH-YIELD ONE-LINER Brepocitinib = oral selective TYK2-JAK1 inhibitor → adult dermatomyositis. For medical students, that one line may be enough to answer a future NEET-PG, INI-CET or FMGE update question. For clinicians, however, the story is more interesting: the Phase 3 VALOR trial showed meaningful improvement in overall dermatomyositis activity, skin disease, physical function and glucocorticoid tapering with the 30-mg dose. Why this approval matters Dermatomyositis is a systemic autoimmune inflammatory myopathy. The classic teaching focuses on proximal muscle weakness, heliotrope rash and Gottron papules, but clinically the disease may involve skin, muscle, joints, lungs and other organs. Treatment has traditionally relied heavily on glucocorticoids and other immunomodulatory therapies, many used off-label. A specifically approved oral targeted therapy therefore represents an important change in the treatment landscape. What exactly is brepocitinib? Brepocitinib is an oral selective inhibitor of TYK2 and JAK1. These kinases participate in intracellular cytokine signaling pathways involved in immune activation and inflammation. Think of the pathway as: Cytokine signal → JAK/TYK signaling → inflammatory gene signaling → immune-mediated tissue injury. By inhibiting TYK2 and JAK1, brepocitinib modifies several inflammatory signaling pathways implicated in dermatomyositis. The study behind the approval: VALOR The pivotal evidence came from the Phase 3 VALOR trial, a double-blind randomized placebo-controlled study involving 241 adults with dermatomyositis. Participants received brepocitinib 30 mg once daily, brepocitinib 15 mg once daily, or placebo for 52 weeks. Background standard therapies were continued and glucocorticoids were tapered. What did the trial show? Group Mean Total Improvement Score at Week 52 Brepocitinib 30 mg 46.5 Brepocitinib 15 mg 37.5 Placebo 31.2 The 30-mg dose was significantly superior to placebo for the primary endpoint. Importantly, brepocitinib 30 mg was also superior across all nine key secondary endpoints, including skin disease activity, systemic glucocorticoid tapering and functional disability. Improvements in some outcomes were observed as early as week 4. It was not just about muscle enzymes One of the clinically attractive aspects of the VALOR results is that benefit was not restricted to a laboratory value. Dermatomyositis can produce persistent and troublesome cutaneous disease even when muscle manifestations are less dramatic. The 30-mg dose demonstrated improvement across clinically relevant domains including skin activity and physical function. The steroid-sparing angle Long-term glucocorticoid exposure carries substantial toxicity, including diabetes, osteoporosis, infection risk, cataracts, hypertension and weight gain. In VALOR, improvement with brepocitinib 30 mg was accompanied by greater glucocorticoid tapering. This makes the result clinically more meaningful than a change in a single disease marker. Does this replace steroids? No. The approval should not be interpreted as meaning that every newly diagnosed patient can simply replace conventional therapy with one tablet. Dermatomyositis is heterogeneous. Treatment decisions still depend on the severity and pattern of muscle disease, dysphagia, respiratory involvement, interstitial lung disease, skin disease, autoantibody profile, malignancy evaluation, previous treatment response and patient-specific risks. Also remember an important trial detail: standard therapies were continued while glucocorticoids were tapered. Brepocitinib adds a new targeted option; it does not erase the need for individualized specialist management. Dose: the number worth remembering The FDA-approved Lisraya tablet contains brepocitinib 30 mg, administered orally once daily for adults with dermatomyositis. Safety: oral does not mean casual Brepocitinib is a potent immunomodulatory therapy. In VALOR, serious infections occurred more frequently with brepocitinib 30 mg than with placebo (10% versus 1%). The FDA prescribing information contains important warnings and precautions, including serious infections, malignancy, major adverse cardiovascular events and thrombosis. Common adverse reactions reported in the FDA medication information include upper respiratory tract infections, headache, fatigue, urinary tract infection, nausea, bronchitis, arthralgia, diarrhea, back pain, falls, influenza and acne. Clinical message: “Oral” should never be confused with “low-risk.” Appropriate patient selection, screening and monitoring remain essential. What should medical students remember? Drug: Brepocitinib Trade name: Lisraya Route: Oral, once daily Dose: 30 mg once daily Mechanism: Selective TYK2-JAK1 inhibitor Indication: Dermatomyositis in adults FDA approval: August 27, 2026 Key trial: VALOR Potential exam question A patient with dermatomyositis is started on a newly FDA-approved oral therapy that selectively inhibits TYK2 and JAK1. Which drug is most likely being prescribed? Answer: Brepocitinib (Lisraya). The bigger lesson: targeted therapy is entering myositis For years, dermatomyositis was taught through its memorable clinical signs: heliotrope rash, Gottron papules and proximal muscle weakness. Those remain fundamental. But modern medicine increasingly asks a second question: which molecular pathways are driving the disease, and can those pathways be targeted? Brepocitinib represents that transition from broad immunosuppression toward more targeted immune modulation. Its ultimate place in treatment algorithms will continue to evolve with real-world experience, longer-term safety data, accessibility and cost. But the 2026 approval itself is already an important milestone in dermatomyositis therapy. Frequently Asked Questions What is the new oral drug for dermatomyositis? Brepocitinib, marketed as Lisraya, was FDA-approved in August 2026 for the treatment of dermatomyositis in adults. What is the mechanism of brepocitinib? Brepocitinib is an oral selective inhibitor of TYK2 and JAK1, modifying cytokine signaling involved in inflammatory and autoimmune pathways. What is the dose of brepocitinib for dermatomyositis? The FDA-approved Lisraya dose is 30 mg orally once daily. Is brepocitinib a JAK inhibitor? Yes. Brepocitinib selectively inhibits TYK2 and JAK1. Is brepocitinib better than steroids for dermatomyositis? The treatments should not be reduced to a simple either-or comparison. In VALOR, background standard therapies were continued while glucocorticoids were tapered. The 30-mg brepocitinib group showed clinical benefit and greater glucocorticoid tapering. What is the most important safety concern? Serious infection risk is important. The FDA label also contains warnings and precautions regarding malignancy, major adverse cardiovascular events and thrombosis. What should NEET-PG and INI-CET students remember? Brepocitinib → oral TYK2-JAK1 inhibitor → adult dermatomyositis. Remember the 30-mg once-daily dose […]

Medicine, NEET PG, NExT, NExT Exam

The Future of Anti-Hypertensive Therapy Explained

Once in 6 Months Blood Pressure Injection: The Future of Anti-Hypertensive Therapy Explained High blood pressure affects millions of people in India — and nearly 1 in 4 adults lives with hypertension, many without knowing it. The real challenge is not just treatment, but taking medicines regularly. Now imagine controlling blood pressure with just two injections per year. A new investigational therapy called zilebesiran may make this possible. Let’s understand it in simple language — clinically relevant, exam-focused, and easy to remember.   Featured Snippet: What Is the Once-in-6-Months Blood Pressure Injection? The once-in-6-months blood pressure injection refers to zilebesiran, an investigational RNA-interference therapy that lowers blood pressure by reducing liver production of angiotensinogen, a key component of the RAAS pathway. A single subcutaneous injection may provide blood pressure control for up to 6 months. 🇮🇳 Why This Matters: Hypertension in India Around 25–30% of Indian adults have hypertension. Many remain undiagnosed or irregular with treatment. Poor medication adherence leads to stroke, heart failure, and kidney disease. This makes long-acting therapies extremely interesting for the future of cardiovascular care. Related reading: [Hypertension management guide] (internal link)   Really? A Once-in-6-Months Anti-Hypertensive Drug? Yes — and this is what makes zilebesiran unique. Unlike conventional drugs that block hormones after formation, this drug works at the gene expression level. Daily pills block RAAS… RNAi stops RAAS from being born.   Mechanism of Action of Zilebesiran Target Liver-produced angiotensinogen (AGT) Method RNA interference (gene silencing) Effect ↓ Angiotensinogen ↓ Angiotensin II formation ↓ Vasoconstriction ↓ Blood pressure This means the drug acts upstream in the RAAS pathway, creating prolonged suppression. Related reading: [RAAS system explained simply] (internal link) Why Only Twice a Year? RNA-interference molecules remain active inside cells for a long time. Because of prolonged intracellular action: One subcutaneous injection suppresses AGT production for ~6 months. Dosing becomes biannual instead of daily. This mirrors what happened in diabetes care when therapy shifted from daily insulin to weekly injections. Clinical Trial Evidence — KARDIA Trials Phase II Study Highlights Double-blind, placebo-controlled trial 672 patients with hypertension Average baseline SBP: 143 mm Hg Key Findings Significant reduction in systolic BP vs placebo Additional benefit on top of standard medications BP lowering sustained for up to 6 months after one dose In some studies, the effect was similar to adding another oral antihypertensive drug. Why Is This a Big Deal? Solves adherence problems: Many patients forget daily pills. Twice-yearly injections could transform compliance. Continuous blood pressure control: No missed doses means more stable BP. Potential use in high-risk patients: Especially those uncontrolled despite multiple medications.   Limitations (Important Clinical Perspective) Still investigational (not routine therapy yet) Long duration means limited dose adjustment Side effects, if any, may persist longer Expected to be costlier initially So no — this does NOT replace current BP medicines yet.   Frequently Asked Questions (FAQ) ❓ What is the once-in-6-months BP injection? It is zilebesiran, an investigational RNA-interference drug that lowers blood pressure by reducing angiotensinogen production in the liver. Is zilebesiran available in India? No. It is currently under clinical trials and not yet approved for routine use. How does it differ from ACE inhibitors or ARBs? ACE inhibitors block hormone action, whereas zilebesiran prevents hormone production upstream. Who may benefit in the future? Patients with poor medication compliance or resistant hypertension may benefit if approved. Is it better than regular tablets? Not necessarily — current drugs remain effective and affordable.   Quick Summary Box Feature Zilebesiran Type RNA interference therapy Target Hepatic angiotensinogen Route Subcutaneous injection Frequency Every 6 months Status Investigational (Phase III underway) Major Advantage Improved adherence   Conclusion Will this replace daily BP tablets? Not yet. But it may represent the next evolution of hypertension treatment — where technology helps solve the biggest real-world problem: patients forgetting medicines. The future of cardiovascular pharmacology is moving toward long-acting, precision-based therapies — and zilebesiran may be one of the first steps in that direction.   References World Health Organization (WHO) ICMR Hypertension Data American College of Cardiology (ACC) trial presentations  

FMGE, INICET, Medical, Medicine, NEET PG, NExT Exam

Must Read Topics in General Medicine for INICET Examination

The INICET tends to blend image-based questions with clinical vignettes, emphasizing practical application over rote learning. Clinical reasoning, such as interpreting lab values or recognizing syndromes from case scenarios, is prioritized. Also, several questions in the last few papers have integrated basic sciences like pathology and microbiology into clinical contexts, so revisiting integrated concepts may give you an edge. For the November INI-CET (Institute of National Importance Combined Entrance Test), General Medicine is a key subject. The exam tends to emphasize clinical knowledge, diagnostics, management protocols, and recent updates. Here’s a structured list of must-know topics for General Medicine preparation: Cardiology – ECG interpretation– MI, arrhythmias, heart blocks, electrolyte disturbances Horizontal ST depression with upright T waves + R/S > 1 in lead V2 HTN patient with SOB and palpitations. On examination, HR= 120 min, irregular with BP= 90/60 mm Hg. Bilateral crackles in both lung fields is seen. Which is not correct? a. Rate control with esmolol b. Warfarin is not used non -valvular atrial fibrillation c. Rhythm control with Amiodarone d. DC shock is not given in persistent AF a a,b b,c b,d – Brugada syndrome vs TTCM -Acute Coronary Syndrome (STEMI/NSTEMI management) – Congestive Heart Failure (CHF) and NYHA Classification – Infective Endocarditis (update ISCVD 2023 update modified Duke’s criteria) – Hypertension – Aortic dissection management based on type A and type B Neurology – Stroke – Types, NIHSS score, thrombolysis, secondary prevention Would you perform thrombolysis a patient with weakness of face and arm weakness for last 1 hour with normal CT scan – Epilepsy – types and GCSE management – Parkinson’s disease vs HD vs PSP – Multiple Sclerosis and Guillain-Barré Syndrome – Meningitis/Encephalitis – Empirical antibiotics, CSF findings – Headache – Migraine, cluster headache, tension headache vs SAH vs GCA Endocrinology – Diabetes Mellitus – Diagnostic criteria of DKA/HHS management – Thyroid Disorders – Hypo- and hyperthyroidism, nodules, malignancy markers – Adrenal Disorders – Addison’s disease, Cushing’s syndrome   – Pituitary Disorders – Acromegaly, SIADH, DI (diabetes insipidus) – MEN Syndrome Pulmonology – Sleep Apnea Syndrome and obesity hypoventilation syndrome – Pulmonary Embolism and DVT – Risk factors, anticoagulation therapy Biker had polytrauma and develops breathing difficulty after 12 hours of injury. Sp02= 85%CT chest is shown. Echo shows Normal cardiac parameters. a. Fat embolism b. Pulmonary embolism c. ARDS d. Pneumothorax – COPD and Asthma – Harrison based guidelines, stepwise management – Interstitial Lung Diseases (ILDs) and Sarcoidosis – Tuberculosis (including MDR-TB management) Gastroenterology and Hepatology – Chronic Liver Disease and Cirrhosis – Child-Pugh score, MELD – Hepatitis – B graphs of Acute and chronic hepatitis B – GI bleed – Upper vs. lower, endoscopic management – Boerrhave vs Stomach volvulus vs Mallory Weiss vs Acute variceal bleeding Nephrology – Acute interstitial nephritis: Eosinophiluria — CIN vs Athero-embolic kidney disease -Fluid and Electrolyte Disorders – Sodium, potassium, calcium disturbances – Acute Kidney Injury (AKI) vs Chronic Kidney Disease (CKD) identification – Glomerulonephritis – RPGN, nephrotic vs nephritic syndrome – Renal replacement therapy – Hemodialysis, CRRT, peritoneal dialysis Rheumatology – Overlap syndrome – Anti synthetase syndrome vs Dermatomyositis vs Polymyositis Systemic Lupus Erythematosus (SLE) – Diagnostic criteria and antibodies – Rheumatoid Arthritis – Treatment protocols (DMARDs, biologics) – Vasculitis syndromes – ANCA-associated vasculitis, Takayasu’s arteritis – Gout and Pseudogout Infectious Diseases – Scrub typhus – Tropical Infections – Dengue, Malaria – HIV/AIDS – ART guidelines, opportunistic infections – COVID-19 and Post-COVID Syndromes -Sepsis and Septic Shock – Management protocols Hematology and Oncology – Leukemia and Lymphoma – Acute vs chronic, Hodgkin’s vs non-Hodgkin’s – Multiple Myeloma and Plasma Cell Disorders – Coagulation Disorders – DIC, hemophilia, thrombophilia – Paraneoplastic Syndromes General Topics & Miscellaneous – Acid-Base Disorders (ABG interpretation) – Shock – Types and management Study Tips  – Solve MCQs from previous INI-CET papers and clinical vignettes. – Focus on latest guidelines and protocols– These are frequently tested. – Give time to integrated questions involving multi-system involvement (e.g., heart and kidney-related disorders). This plan covers high-yield topics that are essential for the exam. Practice application-based questions regularly and ensure you revise the core topics thoroughly.

FMGE, INICET, Medicine, NEET PG, NEETPG2024, NExT, NExT Exam

Contraindications to thrombolysis in Myocardial infarction

Fibrinolytic agents should be given with 30 minutes of arrival to non-PCI capable hospital where transport to PCI capable hospital is not possible or has delay beyond 120 minutes Current recommended regimen is tPA 15 mg bolus followed by 50 mg Intravenously over 30 minutes and 35 mg over the next 30 minutes. In contrast tenecteplase can be given as weight based intravenous bolus over 10 seconds. Clear Contraindications are remembered by mnemonic: HAS-BLEED 1.       Hypertension marked elevation of BP > 180/110 mm Hg at any time during presentation 2.       Aortic dissection suspected 3.       Stroke: Hemorrhagic at any time 4.       Stroke: Non-hemorrhagic in last 1 year 5.       Bleeding (active internal bleed excluding menses) Relative contraindications to fibrinolytic therapy Mnemonic: RIP – AB AB implies has allergy or Bleed in eye/GIT or bleed risk due to hypertension Recent invasive surgical procedure in last 2 weeks INR> 2 due to current use of OAC Prolonged CPR (> 10 minutes) Pregnancy Risk of Allergic reaction with received STK within preceding 5 days to 2 years Hemorrhagic diabetic retinopathy Active Peptic ulcer disease Severe Hypertension   Hemorrhage is the most serious and most frequent complication of thrombolysis. Hemorrhagic stroke can occur in 0.5 to 0.9% of patients treated with fibrinolytic agents

Medicine classes, NEET PG, NEETSS, NExT, NExT Exam

MULTIFOCAL ATRIAL TACHYCARDIA

#NEETPG #NEETSS #USMLE 2 min read Multifocal Atrial Tachycardia: A Diagnostic and Therapeutic Challenge Multifocal atrial tachycardia (MAT) presents a unique challenge for clinicians. Its variable presentation, non-specific symptoms, and potential for mimicking other arrhythmias necessitate a high index of suspicion and a nuanced approach to diagnosis and management. Clinical Presentation: While some patients with MAT may be asymptomatic, common presentations include: Palpitations Dyspnea Lightheadedness Fatigue The hallmark ECG finding in MAT is multiple P wave morphologies preceding each QRS complex, often with a short P-R interval. However, differentiating MAT from sinus tachycardia with varying P wave morphology or atrial flutter with conduction block requires careful analysis. Unveiling the Underlying Cause: Identifying the underlying condition driving MAT is crucial for optimal management. Here are some key areas to consider: Pulmonary Disease: Chronic obstructive pulmonary disease (COPD), acute respiratory failure, and pulmonary embolism can all trigger MAT. Cardiac Insults: Myocarditis, pericarditis, and coronary artery disease can create a substrate for MAT. Electrolyte Imbalances: Derangements in potassium, magnesium, or calcium can disrupt electrical conduction. Other: Stimulant use, upper GI bleed, and even thyrotoxicosis can be associated with MAT.   Therapeutic Strategies: Treatment for MAT revolves around addressing the underlying cause: Pulmonary Optimization: Managing COPD, treating respiratory failure, and anticoagulation for pulmonary embolism are crucial. Electrolyte Correction: Restoring electrolyte balance is essential for normal cardiac conduction. Medications: Calcium channel blockers, beta-blockers, or amiodarone can help control heart rate and rhythm. Catheter Ablation: When medications fail or the arrhythmia is highly symptomatic, catheter ablation targeting the ectopic foci in the atria can be curative.

Scroll to Top